Cibus, Inc.

What they do

Cibus uses its proprietary Rapid Trait Development System (RTDS) to edit plant genes and develop traits that are licensed to seed companies for royalties. The primary focus is on rice herbicide tolerance traits, with a secondary sustainable ingredients program (biofragrances and lauric oils). The company also retains rights to a broader productivity trait portfolio for potential partner-funded development.

Revenue drivers

• Rice herbicide tolerance traits (HT1 and HT3) — Licensed to seed companies for royalties; management estimates over $200 million in potential annual addressable royalties across 5-7 million peak acres in Latin America and the U.S.
• Sustainable ingredients (biofragrances) — Partner-funded development and commercial scale-up; first pre-commercial scale-up payment received in Q4 2025 from a consumer-packaged goods partner.
• Partner-funded productivity traits — Opportunistically pursued through partnerships; no material revenue currently, but potential for future royalties across other crops (e.g., canola, alfalfa).

Recent performance

For Q2 2026, revenue was $0.994 million, down from $1.7 million in Q1 2026, though up from $0.615 million in Q3 2025. Annual revenue declined from $4.3 million in 2024 to $3.6 million in 2025. Net loss improved in 2025 to $-127.1 million from $-251.4 million in 2024. Quarterly net cash usage declined 19% sequentially and 31% year-over-year. Cash and equivalents stood at $20.4 million as of June 30, 2026.

Strategy

Management is focused on converting its technology into revenue through disciplined commercial execution, prioritizing the rice weed management traits in Latin America. The company is advancing a full commercial agreement with Interoc, expanding from two to five rice traits. In sustainable ingredients, the focus is on scaling up initial biofragrance orders and pursuing additional fragrance products. The company continues to streamline operations to preserve capital and concentrate on near-term commercial programs.

Risks

• No commercial revenue contracts — The company has no revenue-generating commercial contracts with seed companies, relying on licensing agreements that are still under negotiation.
• Going concern risk — With $20.4 million cash and negative operating cash flow (e.g., $-50.6 million in 2025), the company needs additional near-term funding to sustain operations.
• Regulatory and commercialization delays — Rice trait launches depend on customer timelines, such as Fedearroz's 2028 target and Albaugh's herbicide registration for a 2029 U.S. launch, which could slip.
• Dependence on partners — The company relies on third-party seed companies and a consumer-packaged goods partner for development, scale-up, and commercialization, making it vulnerable to partner decisions.

Outlook

Management targets initial commercial launches in Latin America in 2028 with Fedearroz and potentially Interoc, and the U.S. launch in 2029 aligned with Albaugh's herbicide registration. Additional scale-up orders for biofragrances are expected in the second half of 2026. The company continues to pursue negotiations with seed companies in Brazil, Argentina, and India.